已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

[Clinical trials on intrathecal pemetrexed treated leptomeningeal metastases from solid tumors].

医学 培美曲塞 化疗 内科学 不利影响 养生 肿瘤科 外科 胃肠病学 顺铂
作者
Zhenyu Pan,Yanqiu Song,Teng‐Jia Jiang,Xiaolin Yang,Guozi Yang
出处
期刊:PubMed [National Institutes of Health]
卷期号:44 (1): 112-119 被引量:8
标识
DOI:10.3760/cma.j.cn112152-20200711-00647
摘要

Objective: To investigate the feasibility, safety and efficacy of intrathecal pemetrexed (IP) treated for patients with leptomeningeal metastases (LM) from solid tumors. Methods: Forty-seven patients receiving pemetrexed intrathecal chemotherapy in the First Hospital of Jilin University from 2017 to 2018 were selected. The study of pemetrexed intrathecal chemotherapy adopted the classical dose-climbing model and included 13 patients with meningeal metastasis of non-small cell lung cancer who had relapsed and refractory after multiple previous treatments including intrathecal chemotherapy. Based on the dose climbing study, 34 patients with meningeal metastasis of solid tumor who did not receive intrathecal chemotherapy were enrolled in a clinical study using pemetrexed as the first-line intrathecal chemotherapy combined with radiotherapy. Kaplan-Meier method and Log rank test were used for survival analysis, and Cox regression model was used for influencing factor analysis. Results: The dose climbing study showed that the maximum tolerated dose of pemetrexed intrathecal chemotherapy was 10 mg per single dose, and the recommended dosing regimen was 10 mg once or twice a week. The incidence of adverse reactions was 10 cases, including hematological adverse reactions (7 cases), transaminase elevation (2 cases), nerve root reactions (5 cases), fatigue and weight loss (1 case). The incidence of serious adverse reactions was 4, including grade 4-5 poor hematology (2 cases), grade 4 nerve root irritation (2 cases), and grade 4 elevated aminotransferase (1 case). In the dose climbing study, 4 patients were effectively treated and 7 were disease controlled. The survival time was ranged from 0.3 to 14.0 months and a median survival time was 3.8 months. The clinical study of pemetrexed intrathecal chemotherapy combined with radiotherapy showed that the treatment mode of 10 mg pemetrexed intrathecal chemotherapy once a week combined with synchronous involved area radiotherapy 40 Gy/4 weeks had a high safety and reactivity. The incidence of major adverse reactions was 52.9% (18/34), including hematologic adverse reactions (13 cases), transaminase elevation (10 cases), and nerve root reactions (4 cases). In study 2, the response rate was 67.6% (23/34), the disease control rate was 73.5% (25/34), the overall survival time was ranged from 0.3 to 16.6 months, the median survival time was 5.5 months, and the 1-year survival rate was 21.6%. Clinical response, improvement of neurological dysfunction, completion of concurrent therapy and subsequent systemic therapy were associated with the overall survival (all P<0.05). Conclusions: Pemetrexed is suitable for the intrathecal chemotherapy with a high safety and efficacy. The recommended administration regimen was IP at 10 mg on the schedule of once or twice per week. Hematological toxicity is the main factor affecting the implementation of IP. Vitamin supplement can effectively control the occurrence of hematological toxicity.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
好兄弟完成签到 ,获得积分10
1秒前
研友_851KE8发布了新的文献求助10
1秒前
1秒前
多多完成签到,获得积分10
3秒前
嗯对完成签到 ,获得积分10
3秒前
温书禾完成签到 ,获得积分10
4秒前
4秒前
memo完成签到 ,获得积分10
4秒前
深情念烟发布了新的文献求助10
5秒前
ggg完成签到 ,获得积分10
5秒前
5秒前
ABJ完成签到 ,获得积分10
6秒前
严明完成签到,获得积分0
7秒前
狂野盼易完成签到,获得积分10
8秒前
film完成签到 ,获得积分10
8秒前
桂鱼完成签到 ,获得积分10
9秒前
深情念烟完成签到,获得积分10
9秒前
zztand完成签到,获得积分10
11秒前
明朗完成签到 ,获得积分10
11秒前
愤怒野猪完成签到 ,获得积分10
11秒前
12秒前
heidi完成签到,获得积分10
12秒前
12秒前
鲜于元珊完成签到,获得积分10
12秒前
12秒前
pinhhoetkuanhp完成签到,获得积分10
12秒前
seanszli完成签到,获得积分10
13秒前
梓泽丘墟完成签到,获得积分0
15秒前
kcaj完成签到,获得积分0
15秒前
武渊思完成签到,获得积分10
15秒前
笙笙的应助被科研通管家采纳,获得10
15秒前
null的应助被科研通管家采纳,获得10
15秒前
华无剑的应助被科研通管家采纳,获得10
16秒前
GingerF的应助被科研通管家采纳,获得50
16秒前
null的应助被科研通管家采纳,获得10
16秒前
Owen的应助被科研通管家采纳,获得10
16秒前
桐桐的应助被科研通管家采纳,获得10
16秒前
隐形曼青的应助被科研通管家采纳,获得10
16秒前
鲁滨孙发布了新的文献求助10
16秒前
852的应助被科研通管家采纳,获得10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184764
求助须知:如何正确求助?哪些是违规求助? 9573733
关于积分的说明 21832921
捐赠科研通 7782115
什么是DOI,文献DOI怎么找? 3434404
关于科研通互助平台的介绍 2558528
邀请新用户注册赠送积分活动 2481067